Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bio-Techne Cp (NQ: TECH )

362.77 -7.29 (-1.97%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 17, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 210,432
Open 365.95
Bid (Size) 190.68 (1)
Ask (Size) 581.13 (1)
Prev. Close 370.06
Today's Range 361.20 - 370.76
52wk Range 318.07 - 543.85
Shares Outstanding 39,233,511
Dividend Yield 0.35%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
NexImmune Price Target Cut By 75%, Plus Wells Fargo Lowers PT Price Target On These Stocks
Raymond James cut the price target for NexImmune, Inc. (NASDAQ: NEXI) from $12 to $3. NexImmune shares rose 2.4% to $1.29 in pre-market trading. 
Via Benzinga
Recap: Bio-Techne Q4 Earnings
  Bio-Techne (NASDAQ:TECH) reported its Q4 earnings results on Thursday, August 4, 2022 at 06:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga

Performance

YTD
-25.63%
-25.63%
1 Month
+7.89%
+7.89%
3 Month
+1.02%
+1.02%
6 Month
-11.96%
-11.96%
1 Year
-23.47%
-23.47%

More News

Read More
Tackling Recurring Health Conditions Offers Hope to Patients
Via FinancialNewsMedia
7 Defensive Growth Stocks to Buy for a Shaky Market
Via InvestorPlace
Recap: Bio-Techne Q3 Earnings
Via Benzinga
Bio-Techne Clocks 17% Organic Revenue Growth In Q2, Announces $400M Share Buyback
Via Benzinga
Earnings Scheduled For November 2, 2021
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022
Via Benzinga
7 Superior Stocks That Smart Investors Will Buy on the Dip
Via InvestorPlace
10 Biggest Price Target Changes For Wednesday
Via Benzinga
The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson's Program
Via Benzinga
Here's How Much You Would Have Made Owning Bio-Techne Stock In The Last 5 Years
Via Benzinga
Bio-Techne Corporation (TECH) Q1 2022 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
Via Benzinga
Exposures COVID-19
Bio-Techne's Earnings: A Preview
Via Benzinga
The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study
Via Benzinga
A Peek Into The Markets: US Stock Futures Rise Ahead Of Economic Data; Crude Oil Gains 1%
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Via Benzinga
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
Via Benzinga
Exposures COVID-19
Director Of Bio-Techne Trades $4.80 Million In Company Stock
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
CFO Of Bio-Techne Trades $6.14 Million In Company Stock
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself
Via Benzinga
The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
Via Benzinga
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.